Viral Vector and Plasmid DNA Manufacturing Market Size, Share Global Analysis Report, 2018 – 2027

Name: Viral Vector and Plasmid DNA Manufacturing Market By Product (Viral Vectors and Plasmid), By End-User (Biopharmaceutical Companies and Research Institutes), and By Application (Gene & Cancer Therapies, Formulation Development, Viral Infections, and Immunotherapy): Global Industry Perspective, Comprehensive Analysis, and Forecast 2018 – 2027
Creator: Facts and Factors
License: https://www.fnfresearch.com/privacy-policy

Press Release

Global Viral Vector and Plasmid DNA Manufacturing Market Revenue Projected Around USD 2,237 Million By 2027

Viral Vector and Plasmid DNA Manufacturing Market By Product (Viral Vectors and Plasmid), By End-User (Biopharmaceutical Companies and Research Institutes), and By Application (Gene & Cancer Therapies, Formulation Development, Viral Infections, and Immunotherapy): Global Industry Perspective, Comprehensive Analysis, and Forecast 2018 – 2027

Industry Insights

The report covers the forecast and analysis of the viral vector and plasmid DNA manufacturing market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Million). The study includes drivers and restraints of the viral vector and plasmid DNA manufacturing market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the viral vector and plasmid DNA manufacturing market on a global level.

Global Viral Vector and Plasmid DNA Manufacturing Market Size

To know more about this report | Request Free Sample Copy

In order to give the users of this report a comprehensive view of the viral vector and plasmid DNA manufacturing market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product & service launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

Report Scope

Report Attributes	Details
Market Size in 2018	USD 418 Million
Projected Market Size in 2027	USD 2,237 Million
CAGR Growth Rate	20.5 % CAGR
Base Year	2017
Forecast Years	2018 – 2027
Key Market Players	Kaneka Corporation (Eurogentec), Cobra Biologics, VGXI, Inc., DNA manufacturing market include Lonza, FUJIFILM Diosynth Biotechnologies Inc., Genzyme Corporation, Vigene Biosciences Inc., Brammer Bio, Oxford Gene Technology, SIRION Biotech GmbH, FinVector Vision Therapies, VIROVEK, Novasep, SPARK THERAPEUTICS, INC., ALDEVRON, and General Electric Company (GE Healthcare).
Key Segment	By Product, By Application, By Region
Major Regions Covered	North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Purchase Options	Request customized purchase options to meet your research needs. Explore purchase options

The study provides a decisive view of the viral vector and plasmid DNA manufacturing market by segmenting the market based on the product, end-user, application, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The rise in the allocation of funds by private organizations for carrying out research activities is predicted to steer the market expansion over the forecast timespan. In addition to this, manufacturers are implementing new technologies like cell line culture development, expression systems, and cell culture system for effectively handling activities related to viral-based vector development. All these aspects will upsurge market growth during the forecast period. Nonetheless, the risk of mutagenesis & other obstructions in gene therapy as well as huge costs associated with gene treatment will put brakes on the growth of the market over the forecast period.

Based on the product, the market is divided into viral Vectors and plasmid. In terms of end-user, the market is sectored into Biopharmaceutical Companies and Research Institutes. Application-wise, the industry is classified into Gene & Cancer Therapies, Formulation Development, Viral Infections, and Immunotherapy.

Some of the key participants in the viral vector and plasmid DNA manufacturing business are

Kaneka Corporation (Eurogentec)
Cobra Biologics
VGXI Inc.
DNA manufacturing market include Lonza
FUJIFILM Diosynth Biotechnologies Inc.
Genzyme Corporation
Vigene Biosciences Inc.
Brammer Bio
Oxford Gene Technology
SIRION Biotech GmbH
FinVector Vision Therapies
VIROVEK
Novasep
SPARK THERAPEUTICS INC.
ALDEVRON
General Electric Company (GE Healthcare)

Table of Content

Chapter 1. Executive Summary 21
Chapter 2. Viral Vector and Plasmid DNA Manufacturing market – Product Analysis 24
- 2.1. Global Viral Vector and Plasmid DNA Manufacturing Market – Product Overview 24
- 2.2. Global Viral Vector and Plasmid DNA Manufacturing Market Share, by Product, 2018 & 2025 (USD Million) 24
- 2.3. Viral Vectors 26
  - 2.3.1. Global Viral Vectors Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 26
- 2.4. Plasmid 27
  - 2.4.1. Global Plasmid Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 27
Chapter 3. Viral Vector and Plasmid DNA Manufacturing market – End-User Analysis 27
- 3.1. Global Viral Vector and Plasmid DNA Manufacturing Market – End-User Overview 27
- 3.2. Global Viral Vector and Plasmid DNA Manufacturing Market Share, by End-User, 2018 & 2025 (USD Million) 28
- 3.3. Biopharmaceutical Companies 29
  - 3.3.1. Global Biopharmaceutical Companies Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 29
- 3.4. Research Institutes 30
  - 3.4.1. Global Research Institutes Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 30
Chapter 4. Viral Vector and Plasmid DNA Manufacturing market – Application Analysis 30
- 4.1. Global Viral Vector and Plasmid DNA Manufacturing Market – Application Overview 30
- 4.2. Global Viral Vector and Plasmid DNA Manufacturing Market Share, by Application, 2018 & 2025 (USD Million) 31
- 4.3. Gene & Cancer Therapies 32
  - 4.3.1. Global Gene & Cancer Therapies Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 32
- 4.4. Formulation Development 33
  - 4.4.1. Global Formulation Development Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 33
- 4.5. Viral Infections 34
  - 4.5.1. Global Viral Infections Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 34
- 4.6. Immunotherapy 35
  - 4.6.1. Global Immunotherapy Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 35
Chapter 5. Viral Vector and Plasmid DNA Manufacturing market – Regional Analysis 36
- 5.1. Global Viral Vector and Plasmid DNA Manufacturing Market Regional Overview 36
- 5.2. Global Viral Vector and Plasmid DNA Manufacturing Market Share, by Region, 2018 & 2025 (Value) 36
- 5.3. North America 38
  - 5.3.1. North America Viral Vector and Plasmid DNA Manufacturing Market size and forecast, 2015-2027 38
  - 5.3.2. North America Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2018 & 2025 (USD Million) 38
  - 5.3.3. North America Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2015-2027 40
    - 5.3.3.1. North America Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2015-2027 (USD Million) 40
  - 5.3.4. North America Viral Vector and Plasmid DNA Manufacturing Market, by End-User, 2015-2027 41
    - 5.3.4.1. North America Viral Vector and Plasmid DNA Manufacturing Market, by End-User, 2015-2027 (USD Million) 41
  - 5.3.5. North America Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2015-2027 42
    - 5.3.5.1. North America Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2015-2027 (USD Million) 42
  - 5.3.6. U.S. 43
    - 5.3.6.1. U.S. Market size and forecast, 2015-2027 (USD Million) 43
  - 5.3.7. Canada 44
    - 5.3.7.1. Canada Market size and forecast, 2015-2027 (USD Million) 44
  - 5.3.8. Mexico 45
    - 5.3.8.1. Mexico Market size and forecast, 2015-2027 (USD Million) 45
- 5.4. Europe 46
  - 5.4.1. Europe Viral Vector and Plasmid DNA Manufacturing Market size and forecast, 2015-2027 46
  - 5.4.2. Europe Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2018 & 2025 (USD Million) 46
  - 5.4.3. Europe Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2015-2027 48
    - 5.4.3.1. Europe Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2015-2027 (USD Million) 48
  - 5.4.4. Europe Viral Vector and Plasmid DNA Manufacturing Market, by End-User, 2015-2027 49
    - 5.4.4.1. Europe Viral Vector and Plasmid DNA Manufacturing Market, by End-User, 2015-2027 (USD Million) 49
  - 5.4.5. Europe Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2015-2027 50
    - 5.4.5.1. Europe Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2015-2027 (USD Million) 50
  - 5.4.6. Germany 51
    - 5.4.6.1. Germany Market size and forecast, 2015-2027 (USD Million) 51
  - 5.4.7. France 52
    - 5.4.7.1. France Market size and forecast, 2015-2027 (USD Million) 52
  - 5.4.8. U.K. 53
    - 5.4.8.1. U.K. Market size and forecast, 2015-2027 (USD Million) 53
  - 5.4.9. Italy 54
    - 5.4.9.1. Italy Market size and forecast, 2015-2027 (USD Million) 54
  - 5.4.10. Spain 55
    - 5.4.10.1. Spain Market size and forecast, 2015-2027 (USD Million) 55
  - 5.4.11. Nordic Countries 56
    - 5.4.11.1. Nordic Countries Market size and forecast, 2015-2027 (USD Million) 56
  - 5.4.12. Benelux Union 57
    - 5.4.12.1. Benelux Union Market size and forecast, 2015-2027 (USD Million) 57
  - 5.4.13. Rest of Europe 58
    - 5.4.13.1. Rest of Europe Market size and forecast, 2015-2027 (USD Million) 58
- 5.5. Asia Pacific 59
  - 5.5.1. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market size and forecast, 2015-2027 59
  - 5.5.2. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2018 & 2025 (USD Million) 59
  - 5.5.3. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2015-2027 61
    - 5.5.3.1. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2015-2027 (USD Million) 61
  - 5.5.4. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by End-User, 2015-2027 62
    - 5.5.4.1. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by End-User, 2015-2027 (USD Million) 62
  - 5.5.5. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2015-2027 63
    - 5.5.5.1. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2015-2027 (USD Million) 63
  - 5.5.6. China 64
    - 5.5.6.1. China Market size and forecast, 2015-2027 (USD Million) 64
  - 5.5.7. Japan 65
    - 5.5.7.1. Japan Market size and forecast, 2015-2027 (USD Million) 65
  - 5.5.8. India 66
    - 5.5.8.1. India Market size and forecast, 2015-2027 (USD Million) 66
  - 5.5.9. New Zealand 67
    - 5.5.9.1. New Zealand Market size and forecast, 2015-2027 (USD Million) 67
  - 5.5.10. Australia 68
    - 5.5.10.1. Australia Market size and forecast, 2015-2027 (USD Million) 68
  - 5.5.11. South Korea 69
    - 5.5.11.1. South Korea Market size and forecast, 2015-2027 (USD Million) 69
  - 5.5.12. South-East Asia 70
    - 5.5.12.1. South-East Asia Market size and forecast, 2015-2027 (USD Million) 70
  - 5.5.13. Rest of Asia Pacific 71
    - 5.5.13.1. Rest of Asia Pacific Market size and forecast, 2015-2027 (USD Million) 71
- 5.6. Latin America 72
  - 5.6.1. Latin America Viral Vector and Plasmid DNA Manufacturing Market size and forecast, 2015-2027 72
  - 5.6.2. Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2018 & 2025 (USD Million) 72
  - 5.6.3. Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2015-2027 74
    - 5.6.3.1. Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2015-2027 (USD Million) 74
  - 5.6.4. Latin America Viral Vector and Plasmid DNA Manufacturing Market, by End-User, 2015-2027 75
    - 5.6.4.1. Latin America Viral Vector and Plasmid DNA Manufacturing Market, by End-User, 2015-2027 (USD Million) 75
  - 5.6.5. Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2015-2027 76
    - 5.6.5.1. Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2015-2027 (USD Million) 76
  - 5.6.6. Brazil 77
    - 5.6.6.1. Brazil Market size and forecast, 2015-2027 (USD Million) 77
  - 5.6.7. Argentina 78
    - 5.6.7.1. Argentina Market size and forecast, 2015-2027 (USD Million) 78
  - 5.6.8. Rest of Latin America 79
    - 5.6.8.1. Rest of Latin America Market size and forecast, 2015-2027 (USD Million) 79
- 5.7. The Middle-East and Africa 80
  - 5.7.1. The Middle-East and Africa Viral Vector and Plasmid DNA Manufacturing Market size and forecast, 2015-2027 80
  - 5.7.2. The Middle-East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2018 & 2025 (USD Million) 80
  - 5.7.3. The Middle-East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2015-2027 82
    - 5.7.3.1. The Middle-East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2015-2027 (USD Million) 82
  - 5.7.4. The Middle-East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by End-User, 2015-2027 83
    - 5.7.4.1. The Middle-East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by End-User, 2015-2027 (USD Million) 83
  - 5.7.5. The Middle-East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2015-2027 84
    - 5.7.5.1. The Middle-East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2015-2027 (USD Million) 84
  - 5.7.6. Saudi Arabia 85
    - 5.7.6.1. Saudi Arabia Market size and forecast, 2015-2027 (USD Million) 85
  - 5.7.7. UAE 86
    - 5.7.7.1. UAE Market size and forecast, 2015-2027 (USD Million) 86
  - 5.7.8. Egypt 87
    - 5.7.8.1. Egypt Market size and forecast, 2015-2027 (USD Million) 87
  - 5.7.9. Kuwait 88
    - 5.7.9.1. Kuwait Market size and forecast, 2015-2027 (USD Million) 88
  - 5.7.10. South Africa 89
    - 5.7.10.1. South Africa Market size and forecast, 2015-2027 (USD Million) 89
  - 5.7.11. Rest of Middle-East Africa 90
    - 5.7.11.1. Rest of Middle-East Africa Market size and forecast, 2015-2027 (USD Million) 90
Chapter 6. Viral Vector and Plasmid DNA Manufacturing market – Competitive Landscape 91
- 6.1. Competitor Market Share – Revenue 91
- 6.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players 93
- 6.3. Strategic Development 94
  - 6.3.1. Acquisitions and Mergers 94
  - 6.3.2. New Products 94
  - 6.3.3. Research & Development Activities 94
Chapter 7. Company Profiles 95
- 7.1. Vigene Biosciences Inc. 95
  - 7.1.1. Company Overview 95
  - 7.1.2. Vigene Biosciences Inc. Revenue and Gross Margin 95
  - 7.1.3. Product portfolio 96
  - 7.1.4. Recent initiatives 97
- 7.2. Lonza 97
  - 7.2.1. Company Overview 97
  - 7.2.2. Lonza Revenue and Gross Margin 97
  - 7.2.3. Product portfolio 98
  - 7.2.4. Recent initiatives 99
- 7.3. FinVector Vision Therapies 99
  - 7.3.1. Company Overview 99
  - 7.3.2. FinVector Vision Therapies Revenue and Gross Margin 99
  - 7.3.3. Product portfolio 100
  - 7.3.4. Recent initiatives 101
- 7.4. Kaneka Corporation (Eurogentec) 101
  - 7.4.1. Company Overview 101
  - 7.4.2. Kaneka Corporation (Eurogentec) Revenue and Gross Margin 101
  - 7.4.3. Product portfolio 102
  - 7.4.4. Recent initiatives 103
- 7.5. VGXI Inc. 103
  - 7.5.1. Company Overview 103
  - 7.5.2. VGXI Inc. Revenue and Gross Margin 103
  - 7.5.3. Product portfolio 104
  - 7.5.4. Recent initiatives 105
- 7.6. VIROVEK 105
  - 7.6.1. Company Overview 105
  - 7.6.2. VIROVEK Revenue and Gross Margin 105
  - 7.6.3. Product portfolio 106
  - 7.6.4. Recent initiatives 107
- 7.7. SIRION Biotech GmbH 107
  - 7.7.1. Company Overview 107
  - 7.7.2. SIRION Biotech GmbH Revenue and Gross Margin 107
  - 7.7.3. Product portfolio 108
  - 7.7.4. Recent initiatives 109
- 7.8. Cobra Biologics 109
  - 7.8.1. Company Overview 109
  - 7.8.2. Cobra Biologics Revenue and Gross Margin 109
  - 7.8.3. Product portfolio 110
  - 7.8.4. Recent initiatives 111
- 7.9. Novasep 111
  - 7.9.1. Company Overview 111
  - 7.9.2. Novasep Revenue and Gross Margin 111
  - 7.9.3. Product portfolio 112
  - 7.9.4. Recent initiatives 113
- 7.10. FUJIFILM Diosynth Biotechnologies Inc. 113
  - 7.10.1. Company Overview 113
  - 7.10.2. FUJIFILM Diosynth Biotechnologies Inc. Revenue and Gross Margin 113
  - 7.10.3. Product portfolio 114
  - 7.10.4. Recent initiatives 115
- 7.11. SPARK THERAPEUTICS INC. 115
  - 7.11.1. Company Overview 115
  - 7.11.2. SPARK THERAPEUTICS INC. Revenue and Gross Margin 115
  - 7.11.3. Product portfolio 116
  - 7.11.4. Recent initiatives 117
- 7.12. Genzyme Corporation 117
  - 7.12.1. Company Overview 117
  - 7.12.2. Genzyme Corporation Revenue and Gross Margin 117
  - 7.12.3. Product portfolio 118
  - 7.12.4. Recent initiatives 119
- 7.13. ALDEVRON 119
  - 7.13.1. Company Overview 119
  - 7.13.2. ALDEVRON Revenue and Gross Margin 119
  - 7.13.3. Product portfolio 120
  - 7.13.4. Recent initiatives 121
- 7.14. Brammer Bio 121
  - 7.14.1. Company Overview 121
  - 7.14.2. Brammer Bio Revenue and Gross Margin 121
  - 7.14.3. Product portfolio 122
  - 7.14.4. Recent initiatives 123
- 7.15. Oxford Gene Technology 123
  - 7.15.1. Company Overview 123
  - 7.15.2. Oxford Gene Technology Revenue and Gross Margin 123
  - 7.15.3. Product portfolio 124
  - 7.15.4. Recent initiatives 125
- 7.16. General Electric Company 125
  - 7.16.1. Company Overview 125
  - 7.16.2. General Electric Company Revenue and Gross Margin 125
  - 7.16.3. Product portfolio 126
  - 7.16.4. Recent initiatives 127
Chapter 8. Viral Vector and Plasmid DNA Manufacturing — Industry Analysis 128
- 8.1. Viral Vector and Plasmid DNA Manufacturing Market – Key Trends 128
  - 8.1.1. Market Drivers 129
  - 8.1.2. Market Restraints 129
  - 8.1.3. Market Opportunities 130
- 8.2. Value Chain Analysis 131
- 8.3. Technology Roadmap and Timeline 132
- 8.4. Viral Vector and Plasmid DNA Manufacturing Market – Attractiveness Analysis 133
  - 8.4.1. By Product 133
  - 8.4.2. By End-User 133
  - 8.4.3. By Application 134
  - 8.4.4. By Region 136
Chapter 9. Marketing Strategy Analysis, Distributors 137
- 9.1. Marketing Channel 137
- 9.2. Direct Marketing 138
- 9.3. Indirect Marketing 138
- 9.4. Marketing Channel Development Trend 138
- 9.5. Economic/Political Environmental Change 139
Chapter 10. Report Conclusion 140
Chapter 11. Research Approach & Methodology 141
- 11.1. Report Description 141
- 11.2. Research Scope 142
- 11.3. Research Methodology 142
  - 11.3.1. Secondary Research 143
  - 11.3.2. Primary Research 144
  - 11.3.3. Models 145
    - 11.3.3.1. Company Share Analysis Model 145
    - 11.3.3.2. Revenue Based Modeling 146
    - 11.3.3.3. Research Limitations 146

List of Figures

FIG. 1 Global Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 25
FIG. 2 Global Viral Vector and Plasmid DNA Manufacturing Market Share, by Product, 2018 & 2025 (USD Million) 26
FIG. 3 Global Viral Vectors Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 28
FIG. 4 Global Plasmid Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 29
FIG. 5 Global Viral Vector and Plasmid DNA Manufacturing Market Share, by End-User, 2018 & 2025 (USD Million) 30
FIG. 6 Global Biopharmaceutical Companies Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 31
FIG. 7 Global Research Institutes Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 32
FIG. 8 Global Viral Vector and Plasmid DNA Manufacturing Market Share, by Application, 2018 & 2025 (USD Million) 33
FIG. 9 Global Gene & Cancer Therapies Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 34
FIG. 10 Global Formulation Development Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 35
FIG. 11 Global Viral Infections Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 36
FIG. 12 Global Immunotherapy Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 (USD Million) 37
FIG. 13 Global Viral Vector and Plasmid DNA Manufacturing Market Share, by Region, 2018 & 2025 38
FIG. 14 North America Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 40
FIG. 15 U.S. Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 45
FIG. 16 Canada Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 46
FIG. 17 Mexico Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 47
FIG. 18 Europe Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 48
FIG. 19 Germany Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 53
FIG. 20 France Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 54
FIG. 21 U.K. Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 55
FIG. 22 Italy Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 56
FIG. 23 Spain Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 57
FIG. 24 Nordic Countries Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 58
FIG. 25 Benelux Union Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 59
FIG. 26 Rest of Europe Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 60
FIG. 27 Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 61
FIG. 28 China Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 66
FIG. 29 Japan Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 67
FIG. 30 India Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 68
FIG. 31 New Zealand Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 69
FIG. 32 Australia Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 70
FIG. 33 South Korea Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 71
FIG. 34 South-East Asia Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 72
FIG. 35 Rest of Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 73
FIG. 36 Latin America Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 74
FIG. 37 Brazil Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 79
FIG. 38 Argentina Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 80
FIG. 39 Rest of Latin America Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 81
FIG. 40 The Middle-East and Africa Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 82
FIG. 41 Saudi Arabia Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 87
FIG. 42 UAE Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 88
FIG. 43 Egypt Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 89
FIG. 44 Kuwait Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 90
FIG. 45 South Africa Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 91
FIG. 46 Rest of Middle-East Africa Viral Vector and Plasmid DNA Manufacturing Market, 2015-2027 92
FIG. 47 Competitor Market Share – Revenue 93
FIG. 48 Vigene Biosciences Inc. Revenue and Growth Rate 98
FIG. 49 Vigene Biosciences Inc. Market Share 98
FIG. 50 Lonza Revenue and Growth Rate 100
FIG. 51 Lonza Market Share 100
FIG. 52 FinVector Vision Therapies Revenue and Growth Rate 102
FIG. 53 FinVector Vision Therapies Market Share 102
FIG. 54 Kaneka Corporation (Eurogentec) Revenue and Growth Rate 104
FIG. 55 Kaneka Corporation (Eurogentec) Market Share 104
FIG. 56 VGXI Inc. Revenue and Growth Rate 106
FIG. 57 VGXI Inc. Market Share 106
FIG. 58 VIROVEK Revenue and Growth Rate 108
FIG. 59 VIROVEK Market Share 108
FIG. 60 SIRION Biotech GmbH Revenue and Growth Rate 110
FIG. 61 SIRION Biotech GmbH Market Share 110
FIG. 62 Cobra Biologics Revenue and Growth Rate 112
FIG. 63 Cobra Biologics Market Share 112
FIG. 64 Novasep Revenue and Growth Rate 114
FIG. 65 Novasep Market Share 114
FIG. 66 FUJIFILM Diosynth Biotechnologies Inc. Revenue and Growth Rate 116
FIG. 67 FUJIFILM Diosynth Biotechnologies Inc. Market Share 116
FIG. 68 SPARK THERAPEUTICS INC. Revenue and Growth Rate 118
FIG. 69 SPARK THERAPEUTICS INC. Market Share 118
FIG. 70 Genzyme Corporation Revenue and Growth Rate 120
FIG. 71 Genzyme Corporation Market Share 120
FIG. 72 ALDEVRON Revenue and Growth Rate 122
FIG. 73 ALDEVRON Market Share 122
FIG. 74 Brammer Bio Revenue and Growth Rate 124
FIG. 75 Brammer Bio Market Share 124
FIG. 76 Oxford Gene Technology Revenue and Growth Rate 126
FIG. 77 Oxford Gene Technology Market Share 126
FIG. 78 General Electric Company Revenue and Growth Rate 128
FIG. 79 General Electric Company Market Share 128
FIG. 80 Market Dynamics 130
FIG. 81 Global Viral Vector and Plasmid DNA Manufacturing – Value Chain Analysis 133
FIG. 82 Technology Roadmap and Timeline 134
FIG. 83 Market Attractiveness Analysis – By Product 135
FIG. 84 Market Attractiveness Analysis – By End-User 136
FIG. 85 Market Attractiveness Analysis – By Application 136
FIG. 86 Market Attractiveness Analysis – By Region 138
FIG. 87 Market Channel 139
FIG. 88 Marketing Channel Development Trend 140
FIG. 89 Growth in World Gross Product, 2008-2018 141

List of Tables

TABLE 1 Global Viral Vector and Plasmid DNA Manufacturing Market, 2018 & 2025 (USD Million) 24
TABLE 2 Global Viral Vector and Plasmid DNA Manufacturing market, by Product, 2015-2027 (USD Million) 26
TABLE 3 Global Viral Vector and Plasmid DNA Manufacturing market, by End-User, 2015-2027 (USD Million) 30
TABLE 4 Global Viral Vector and Plasmid DNA Manufacturing market, by Application, 2015-2027 (USD Million) 33
TABLE 5 Global Viral Vector and Plasmid DNA Manufacturing market, by Region, 2015-2027 (USD Million) 38
TABLE 6 North America Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2015-2027 (USD Million) 42
TABLE 7 North America Viral Vector and Plasmid DNA Manufacturing Market, by End-User, 2015-2027 (USD Million) 43
TABLE 8 North America Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2015-2027 (USD Million) 44
TABLE 9 Europe Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2015-2027 (USD Million) 50
TABLE 10 Europe Viral Vector and Plasmid DNA Manufacturing Market, by End-User, 2015-2027 (USD Million) 51
TABLE 11 Europe Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2015-2027 (USD Million) 52
TABLE 12 Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2015-2027 (USD Million) 63
TABLE 13 Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by End-User, 2015-2027 (USD Million) 64
TABLE 14 Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2015-2027 (USD Million) 65
TABLE 15 Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2015-2027 (USD Million) 76
TABLE 16 Latin America Viral Vector and Plasmid DNA Manufacturing Market, by End-User, 2015-2027 (USD Million) 77
TABLE 17 Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2015-2027 (USD Million) 78
TABLE 18 The Middle-East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2015-2027 (USD Million) 84
TABLE 19 The Middle-East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by End-User, 2015-2027 (USD Million) 85
TABLE 20 The Middle-East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2015-2027 (USD Million) 86
TABLE 21 Global Viral Vector and Plasmid DNA Manufacturing Market - Company Revenue Analysis 2015-2018 (USD Million) 93
TABLE 22 Global Viral Vector and Plasmid DNA Manufacturing Market - Company Revenue Share Analysis 2015-2018(%) 95
TABLE 23 Acquisitions and Mergers 96
TABLE 24 New Product/Service Launch 96
TABLE 25 Research & Development Activities 96
TABLE 26 Market Drivers 131
TABLE 27 Market Restraints 131
TABLE 28 Market Opportunities 132